Pain relief without the risk: why SRP-001 could change everything
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
List view / Grid view
A practicing surgeon turned biotech CEO is developing a novel pain medicine that could sidestep the failures of both opioids and paracetamol.
Forget the buzzwords - SLAS 2025 showed what’s genuinely driving progress in drug discovery: usable AI, collaborative platforms and tools that solve real problems.
Novartis has teamed up with PTC Therapeutics to develop PTC518, a groundbreaking treatment that targets the cause of Huntington's disease, offering new hope for patients.
Insilico Medicine’s AI-designed drug ISM5939 has received FDA IND clearance for treating solid tumours. By targeting ENPP1, it enhances anti-tumour immunity and is set to begin Phase I trials soon.
Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.
Researchers screened over 2,000 small molecules and have now more than doubled the known compounds reported to induce trained immunity.
PVP-037, identified through a small molecule screen, induces a more durable and broader immune response to vaccines.
In this episode, we discuss how new insights into stem cell biology are leading to novel therapeutics in regenerative medicine beyond cell therapy.
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
Researchers from the University of Freiburg and the University of Cambridge have observed live cell formation of membraneless molecular aggregates, uncovering the interplay between biological mechanisms and physical force.
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.